天瑞仪器(300165) - 2021 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2021 was ¥405,480,042.75, representing a 32.48% increase compared to ¥306,057,731.95 in the same period last year[22]. - The net profit attributable to shareholders of the listed company reached ¥14,883,480.37, a significant turnaround from a loss of ¥18,577,151.11 in the previous year, marking an increase of 180.12%[22]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥14,145,665.44, compared to a loss of ¥28,403,167.35 last year, reflecting a 149.80% improvement[22]. - The basic earnings per share were ¥0.0299, a recovery from a loss of ¥0.0402 per share in the same period last year, indicating a 174.38% increase[22]. - The total comprehensive income attributable to the parent company was CNY 14,883,480.37, compared to a loss of CNY 18,577,151.11 in the first half of 2020[179]. - The company reported a net profit of 149,454,384 CNY, reflecting a strong performance in its core business segments[75]. - The company reported a net loss of CNY 9,234,000 for the first half of 2021[192]. - The total comprehensive income for the period was reported at 7,151 million yuan, which is a decrease of 18.57% from the previous year[191]. Assets and Liabilities - Total assets at the end of the reporting period were ¥2,916,356,802.10, up 13.72% from ¥2,564,439,469.59 at the end of the previous year[22]. - The company's total assets as of June 30, 2021, amounted to CNY 2,916,356,802.10, an increase from CNY 2,564,439,469.59 at the end of 2020[165]. - The total liabilities rose to CNY 1,168,502,607.09 from CNY 825,379,245.12, indicating an increase of around 41.7%[167]. - The company's total liabilities decreased to CNY 539,596,312.17 from CNY 548,012,527.16 at the end of 2020, indicating improved financial stability[172]. - The total equity attributable to shareholders increased to CNY 1,939,880,228.87 from CNY 1,910,578,900.70 at the end of 2020, reflecting positive retained earnings[172]. Cash Flow - The net cash flow from operating activities was negative at -¥265,031,778.65, worsening from -¥91,269,185.74 in the same period last year, reflecting a decline of 190.38%[22]. - The company reported a significant decline in cash flow from operating activities, with a net outflow of ¥265,031,778.65, a decrease of 190.38% year-on-year, attributed to increased procurement for PPP projects[37]. - The company reported a net cash outflow from operating activities of CNY -265,031,778.65, worsening from CNY -91,269,185.74 in the first half of 2020[182]. - Cash and cash equivalents at the end of the first half of 2021 were CNY 269,467,155.97, down from CNY 455,222,662.28 at the beginning of the period[183]. Research and Development - Research and development expenses increased by 39.53% to ¥38,730,590.33, mainly due to an increase in R&D projects[37]. - The company has a strong R&D capability, continuously enriching its product range and expanding into new application areas[29]. - The company is focusing on the development of new technologies in wastewater treatment, with investments amounting to 20,000,000 CNY in related R&D activities[76]. - The company emphasized the importance of R&D investment to enhance core competitiveness and expand product lines in environmental monitoring, food safety, and medical testing[87]. Market and Business Strategy - The company plans to continue expanding its R&D efforts and is focusing on enhancing its product offerings in the environmental monitoring sector[37]. - The company plans to expand its market presence through the establishment of new subsidiaries, including Tianlan Xiangrui and Hunan Beixi, which are expected to contribute positively to future earnings[77]. - The company is actively pursuing mergers and acquisitions to strengthen its market position, having previously acquired 100% of Shanghai Beixi Biotechnology Co., Ltd. for 36,000,000 CNY[79]. - The company is committed to enhancing its service offerings in environmental monitoring and consulting, which are expected to drive future revenue streams[77]. Risks and Compliance - The management has highlighted potential risks and corresponding measures in the report, which investors are advised to review carefully[4]. - The company faced risks from intensified market competition and potential declines in gross margins due to price competition with foreign manufacturers[86]. - The company maintains compliance with national laws and regulations, focusing on both economic and social benefits[98]. - The company has not reported any significant mergers or acquisitions during this period, focusing instead on organic growth strategies[189]. Shareholder Information - The company completed a non-public issuance of 6,805,040 shares on January 12, 2021, increasing the total share capital from 490,185,830 to 496,990,870[128]. - The total number of ordinary shareholders at the end of the reporting period was 22,859[148]. - Liu Zhaogui, a major shareholder, holds 29.04% of the shares, totaling 4,326,306 shares, with a decrease of 9,939,817 shares during the reporting period[149]. - The company has not reported any strategic investors or general legal entities becoming top ten shareholders due to new share subscriptions[149]. Legal Matters - The company reported a total of 3,000,000 yuan involved in a lawsuit with Shenzhen Kangmei Biological Technology Co., Ltd., which is currently in the second instance of trial[107]. - Another lawsuit with Jiangxi Maiwang Environmental Technology Co., Ltd. involves 628,000 yuan and is awaiting further court hearings[107]. - The company has not faced any major litigation or arbitration matters during the reporting period[106]. Dividend Policy - The company plans not to distribute cash dividends or issue bonus shares for this reporting period[6]. - The company did not distribute any dividends during this reporting period, maintaining a focus on reinvestment[189].